



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

In re Application of:
Dmitry Gabrilovich *et al.*

Serial No.: 09/526,320

Filed: March 15, 2000

For: DENDRITIC CELLS TRANSDUCED
WITH A WILD-TYPE SELF GENE
ELICIT POTENT ANTITUMOR IMMUNE
RESPONSES

Group Art Unit: 1632

Examiner: Anne M. Beckerleg

Atty. Dkt. No.: INRP:074US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 11, 2002

Date

Robert E. Hanson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure

Statement is not to be construed as a representation that a search has been made, and is not to be

10/18/2002 10:00:00 AM 00000138 0558301

01/18/2003

18/00 07

10/18/2002 10:00:00 AM 00000138 0558301

25219640.1

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski Account No.: 50-1212/INRP:074US.

Applicants respectfully request that the listed document be made of record in the present case.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 11, 2002



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

16328
RECEIVED


OCT 24 2002

TECH CENTER 1600/2900

RHANSON@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3085

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

October 11, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 11, 2002	
Date	Robert E. Hanson

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/526,320 entitled "DENDRITIC CELLS
TRANSDUCED WITH A WILD-TYPE SELF GENE ELICIT POTENT
ANTITUMOR IMMUNE RESPONSES" by Dmitry Gabrilovich et al.
Our Reference: INRP:074US*


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and reference (A29).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is hereby authorized to deduct any necessary fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/INRP:074US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Robert E. Hanson
Reg. No. 42,628

REH/cmb
Encl.: as noted

25219644.1